A multicenter controlled clinical trial on the improvement of sepsis-associated CCI muscular dystrophy by time-sharing administration(Day-3-Night-2) of Huanglian Decoctio
- Conditions
- Sepsis-related Chronic Care Illnesses
- Registration Number
- ITMCTR2024000045
- Lead Sponsor
- Jiangsu Provincial Hospital of Chinese Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
1) Those who met the diagnostic criteria of sepsis-related CCI.
2) Age between 18 and 85 years old, gender is not limited.
3) Receive enteral nutrition therapy.
4)No serious metabolic disease and other diseases of the digestive tract, such as radiation enteritis and broken bowel syndrome.
5) Informed consent and volunteer to be tested.
Exclusion Criteria
1) ICU stay less than 14 days.
2) Mechanical intestinal obstruction, gastrointestinal hemorrhage.
3) Refusal or inability to perform enteral nutrition therapy.
4) Frequent death or failure of resuscitation, inability to cooperate or refusal to complete the relevant examination.
5) Pregnant and lactating women.
6) Patients who are participating in clinical trials of other drugs.
Study & Design
- Study Type
- Interventional study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Thickness of the median femoral, rectus femoris, and tibialis anterior muscles measured by ultrasound, and cross-sectional area of the rectus femoris muscle;Diaphragmatic indicators (thickness, rate of change, mobility) measured by ultrasound;Ultrasound-measured intra-abdominal fat thickness, including subcutaneous and visceral fat thicknesses;
- Secondary Outcome Measures
Name Time Method 28- and 90-day survival rates;NRS2002 score;Serum nutritional indicators: haemoglobin, albumin, prealbumin and testosterone;APACHE II score;SOFA score;NUTRIC score;